□四川日报全媒体记者 彭瑀珩 当沪指站稳3800点、创业板指逼近2700点，A股指数屡创新高的同时，一场高价股与翻倍股的扩 容热潮正悄然而至。截至8月22日，A股百元股数量较年初近乎翻倍，两个月内新增翻倍股超200 只。 这波行情中，川股也呈现出"双面性"：既有乐山电力短期异动，也有新易盛股价飙涨的牛气。其 真实投资价值究竟如何？哪些标的能穿越行情周期？这些都值得长期关注。 截至8月22日，川股的"提价扩量"态势已清晰显现。从百元股来看，数量从年初的6只增至7只，看 似仅增1只，含金量却显著提升——不仅首次出现200元、300元级别的标的，且新增成员来自硬科 技赛道；年内股价翻倍的川股数量则达到17只。 新易盛堪称川股"涨幅王"，凭借率先实现800G光模块大规模量产，并切入全球头部AI算力厂商供 应链的优势，股价从年初的115.58元一路上涨，最新收盘价达273.81元，在川股中仅次于百利天 恒。极米科技则以消费电子赛道少有的稳健节奏跻身百元股，股价从年初的98元涨至121.56元， 涨幅24%，成为A股"科技+消费电子"领域的典型成长样本。 新股开发科技同样表现亮眼，上市首日便获市场关注，依托新能源研发创新 ...

"2025贵在一心大湾区贵商首发大会"将于9月7日在广州举行。大会旨在搭建高端平台，促进黔粤两地产 业、资本、人才、技术的深度协同。 相关附件 据大会总策划、广州市贵州商会会长赵辉表示，本次大会将聚焦人工智能、新能源、高端装备、新一代 通信技术、生物科技、新型商业模式等战略性新兴产业。大会精心策划的"TOP20首发路演项目"，将集 中展示大湾区贵商在科技创新、产业转型、商业模式上的突破性成果。其中"具身智能机器人灵巧 手""无人机智能应用"等多项全球首发项目更是这场首发大会中闪耀夺目的亮点。 ...

瑞银将康方生物加入该行的亚太主要推荐股票名单，认为其主要资产依达方的海外潜力并未于股价全面 反映，该行又认为，有关与跨国企业潜在合作的报道及将在2025年世界肺癌大会发布的HARMONi研 究，为正面的股价催化剂。另一项关键资产开坦尼亦正展开全球注册研发。该行指，康方生物估值大致 处于该行覆盖生物科技股的中位数，该股有空间进一步跑赢。该行上调对依达方海外高峰销售预估，由 146亿美元上调至163亿美元，对开坦尼的海外高峰销售预估由22亿美元上调至34亿美元。目标价由 197.5港元上调至224.3港元，评级"买入"。 消息面上，近日，康方生物公布，2025年世界肺癌大会(WCLC)将于9月6日-9日在西班牙巴塞罗那举 行。会议期间，康方生物海外合作伙伴Summit Therapeutics，将重磅发布公司全球首创PD-1/VEGF双特 异性抗体新药依沃西首个国际多中心注册性Ⅲ期临床HARMONi研究的结果，该研究结果作为Late- Breaking Abstract(LBA)被大会选为口头报告，将在全体会议主席专题研讨会(Presidential Symposium)上 重磅发布。 康方生物(09926)涨超 ...

Market Performance - The China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 1.5% [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 1.3% [1] - The China Securities Biotechnology Theme Index and the China Securities Innovative Drug Industry Index both saw an increase of 0.7% and 0.5% respectively [1] - The CSI 300 Pharmaceutical and Health Index grew by 0.6% [1] - The Hang Seng Innovative Drug ETF (159316) experienced a net subscription of 18 million units, reaching a record high of 1.26 billion yuan [1] Index Details - The Biotechnology ETF tracks the China Securities Biotechnology Theme Index, which focuses on leading A-share biotechnology companies involved in gene diagnosis, biopharmaceuticals, blood products, and other human biotechnology [4] - The rolling price-to-earnings (P/E) ratio for the Biotechnology Theme Index is 55.3 times, with a valuation percentile of 0.7% [5] - The Pharmaceutical ETF tracks the CSI 300 Pharmaceutical and Health Index, covering major companies in the pharmaceutical and health sector, including chemical pharmaceuticals, medical services, and medical devices [6][7] - The rolling P/E ratio for the CSI 300 Pharmaceutical and Health Index is 30.7 times, with a valuation percentile of 45.7% [7] ETF Characteristics - The Hang Seng Innovative Drug ETF is the only ETF tracking the innovative drug index, with a low management fee of 0.15% per year and a custody fee of 0.05% per year [9]

Core Viewpoint - The establishment of Shennongjia Zhongyue Oasis Biotechnology Co., Ltd. indicates a growing interest in the agricultural and biotechnology sectors, with a focus on various agricultural products and services [1] Company Summary - Shennongjia Zhongyue Oasis Biotechnology Co., Ltd. was recently founded with a registered capital of 5 million RMB [1] - The legal representative of the company is Han Daiju [1] - The company is primarily owned by Chengdu Douqi Culture Communication Co., Ltd. (80%) and Sichuan New Oasis Electric Power Sales Co., Ltd. (20%) [1] Business Scope - The company’s business activities include technology services, development, consulting, and transfer, as well as the production, sales, processing, transportation, and storage of agricultural products [1] - It also engages in the wholesale and retail of edible agricultural products, health food sales, and the cultivation of edible fungi and traditional Chinese medicine [1] - The company is involved in various sales activities, including daily necessities, cosmetics, and jewelry, along with information technology and IoT services [1] - Certain activities require licenses, such as edible fungus seed operations and beverage production [1] Industry Context - The company operates within the manufacturing industry, specifically in the beverage manufacturing sector [1] - The registered address is located in Shennongjia Forest District, Hubei Province [1] - The business is set to operate until at least August 14, 2025, with no fixed end date [1]

Core Viewpoint - The A-share financing balance has surpassed 20 trillion yuan, reaching a nearly ten-year high, indicating strong market interest in the brokerage sector, particularly in broker ETFs, which have seen significant inflows and nearly doubled in size over the past eight weeks [1][4]. Short-term Dynamics - Market risk appetite has improved, with the Shanghai Composite Index and the securities sector showing year-to-date gains of 8.82% and 2.95%, respectively, suggesting potential for further gains in the brokerage sector [4]. - As of August 11, the total financing balance in the A-share market reached 20.05689 trillion yuan, marking a significant increase and reflecting heightened market sentiment [4]. - The current A/H share premium for brokerage stocks is low, with Hong Kong's securities index up 49.92% year-to-date, while A-share brokerage stocks have only increased by an average of 4.63% [4]. - Institutional investors are underweight in the brokerage sector, with active equity funds allocating only 0.64% to brokerages, significantly below the five-year high of 2.0%, indicating potential for increased capital inflows [5]. Mid-term Support - The brokerage sector's net profit for Q1 2025 grew by 83% year-on-year, driven by strong performance in investment and brokerage businesses [8]. - A significant number of brokerages have issued positive mid-year profit forecasts, with many expecting substantial year-on-year growth, which could act as a catalyst for the sector's performance [8]. - The trend of mergers and acquisitions within the brokerage industry is intensifying, with several notable transactions indicating a focus on internal consolidation [8]. Long-term Trends - There is a growing interest in Chinese assets, with various investment themes attracting capital in both A-shares and Hong Kong stocks [11]. - The internationalization of the renminbi is providing new momentum for brokerage firms, with a notable increase in cross-border transactions and services [11]. - The brokerage sector is positioned at a critical juncture for value reassessment and upward trends, with low-cost investment tools like broker ETFs offering efficient market access for investors [12].

Core Viewpoint - Overseas long-term funds are intensively conducting due diligence on Chinese asset managers, indicating a renewed interest in China's investment opportunities after a three-year hiatus [1][2]. Group 1: Due Diligence Activities - Numerous Chinese asset managers, including domestic and overseas Chinese investment institutions, have undergone due diligence from overseas long-term funds in the past quarter [3]. - APS, a Singapore asset management firm, has seen significant capital inflow from both domestic and Singaporean investors, including family offices and high-net-worth individuals [3]. - Overseas institutions are particularly interested in the historical holdings and trading decisions of asset managers to understand their investment style and sources of returns [3][4]. Group 2: Investment Process and Preferences - Establishing a long-term partnership requires asset managers to have a scalable and repeatable investment process; inconsistency in performance can lead to skepticism from overseas institutions [4]. - Overseas investors are focusing on seven key areas during due diligence, including investment management systems, risk management capabilities, organizational structure, alignment of interests, fee structures, macroeconomic outlook, and geopolitical risk assessments [5]. - There is a notable interest from overseas family offices and funds of funds (FOFs) in absolute return-oriented investment strategies and products [4][5]. Group 3: Market Sentiment and Future Outlook - Despite some overseas institutions showing interest, pension funds and sovereign wealth funds have not yet made significant adjustments to their allocations [6]. - The return of North American pension funds to China is anticipated around 2026, contingent on favorable market conditions and performance [7][9]. - Global funds are currently underweight in China, with a 11% allocation level, significantly lower than the benchmark, indicating a cautious approach due to past market volatility and economic uncertainties [8][9]. Group 4: Investment Opportunities in Technology - There is a shift in focus towards hard technology sectors, with a particular emphasis on the semiconductor industry, which is seen as a key area for China's future growth [12][14]. - Companies like SMIC are highlighted for their potential, with expectations of significant improvements in return on equity (ROE) over the next few years [12][13]. - The changing landscape in China, including reduced importance of real estate and shifts in industrial policy, presents new opportunities for global investors to engage with emerging Chinese enterprises [14].

Core Viewpoint - The Vietnamese Communist Party emphasizes the crucial role of intellectuals, scientists, and artists in national development and stability, especially in the context of rapid global changes and technological advancements [1][2]. Group 1: Importance of Intellectuals and Scientists - The Vietnamese leadership acknowledges the significant contributions of intellectuals, scientists, and artists to the nation's historical development [1]. - The current era is characterized by knowledge as a key resource for development, necessitating the active participation of these groups to adapt to changes brought by the Fourth Industrial Revolution and digital transformation [1]. Group 2: Focus Areas for Development - Intellectuals, scientists, and artists are encouraged to focus on key areas such as technology, education, healthcare, high-tech agriculture, digital economy, digital society, green energy transition, and circular economy to support sustainable national development [2]. Group 3: Ethical Standards and Responsibilities - There is a strong emphasis on the need for these professionals to uphold ethical standards, integrity, and social responsibility, particularly in an era where misinformation and artificial intelligence can create false content [2]. - The qualities of integrity and honesty are highlighted as essential for defending truth and building a healthy society [2]. Group 4: Support from the Government - The Vietnamese government is committed to creating conditions for intellectuals, scientists, and artists to fully utilize their talents and creativity for national development [2]. - There is confidence that these groups will continue to lead and inspire the nation towards a prosperous future [2].

Group 1 - The core viewpoint of the news is that the Nasdaq Biotechnology Index (NBI) has shown resilience and growth amid rising expectations for interest rate cuts by the Federal Reserve, with the NBI increasing by 2.06% [1] - The Nasdaq Biotechnology ETF (513290) has experienced significant inflows, rising by 0.85% as of 10:58 AM on August 5, marking three consecutive days of net inflows over the past five trading days [1][3] - Key component stocks of the Nasdaq Biotechnology ETF have mostly risen, with Summit Therapeutics (SMMT) up over 8%, and other notable increases from Alnylam Pharmaceuticals (ALNY) and Regeneron Pharmaceuticals (REGN) [3][4] Group 2 - Vertex Pharmaceuticals (VRTX) reported a 2.19% increase in stock price with a trading volume of 1.07 billion, while Amgen (AMGN) rose by 1.70% with a trading volume of 695 million [4] - Vertex Pharmaceuticals is projected to have total revenue of $2.96 billion in Q2 2025, reflecting a 12% year-over-year growth, while its non-GAAP net profit for Q2 is expected to be $1.2 billion [6] - The Federal Reserve's interest rate cut expectations have increased significantly, with an 80% probability of a rate cut in September and a 50% chance of another cut in October, driven by weaker-than-expected non-farm payroll data [6][8] Group 3 - The Nasdaq Biotechnology Index (NBI) serves as a benchmark for global innovative pharmaceuticals, including top biotech companies listed on Nasdaq, and is weighted by market capitalization [12] - The Nasdaq Biotechnology ETF (513290) is the only ETF that focuses on global innovative pharmaceuticals, allowing investors to access leading biotech firms with a low entry point [12] - The combination of potential interest rate cuts, ongoing AI innovations, and increased merger and acquisition activity is expected to catalyze a new wave of growth in the biotech sector [12]

Group 1 - The stock price of Sichuan Shuangma closed at 19.33 yuan on August 4, 2025, with a slight decrease of 0.02 yuan, representing a drop of 0.10% [1] - The company reported a trading volume of 1.58 billion yuan, with a fluctuation of 1.91% and a turnover rate of 1.08% on the same day [1] - Sichuan Shuangma's main business includes cement and building materials, while also venturing into biotechnology and medical aesthetics [1] Group 2 - The company aims to continuously promote the development of its core business and focus on high-growth industries such as biotechnology [1] - Sichuan Shuangma is seeking synergistic business opportunities to enhance its long-term competitiveness [1] - In investor interactions, the company expressed its commitment to optimizing its business layout and enhancing investor confidence through performance growth and development prospects [1] Group 3 - On August 4, the net inflow of main funds was 3.6693 million yuan, with a cumulative net inflow of 22.8371 million yuan over the past five days [1]